Dishman Pharmaceuticals rises on receiving EIR for Bavla facility

02 Feb 2017 Evaluate

Dishman Pharmaceuticals and Chemicals is currently trading at Rs. 235.20, up by 7.25 points or 3.18% from its previous closing of Rs. 227.95 on the BSE.

The scrip opened at Rs. 236.70 and has touched a high and low of Rs. 238.35 and Rs. 234.40 respectively. So far 36,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 267.95 on 30-Sep-2016 and a 52 week low of Rs. 127.60 on 24-Jun-2016.

Last one week high and low of the scrip stood at Rs. 238.35 and Rs. 220.70 respectively. The current market cap of the company is Rs. 3,795.00 crore.

The promoters holding in the company stood at 61.40%, while Institutions and Non-Institutions held 22.95% and 15.65% respectively.

Dishman Pharmaceuticals and Chemicals has received Establishment Inspection Report (EIR) from the USFDA for its Bavla facility on February 01, 2017. Thus, the company’s facilities in Bavla, Naroda and Switzerland continue to be approved by the USFDA. The US Food and Drug Administration (USFDA) had inspected Bavla facility in July, 2016.

Dishman Pharmaceuticals and Chemicals is a global outsourcing partner for the pharmaceutical industry, offering a portfolio of development, scale-up and manufacturing services. It improves its customers’ businesses by providing a range of development and manufacturing solutions at locations in Europe and in India.


Peers
Company Name CMP
Sun Pharma Inds. 1774.95
Dr. Reddys Lab 1209.20
Cipla 1484.05
Lupin 2056.15
Zydus Lifesciences 944.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.